TOH edition: Friday, 9 October 2026 · Health & Medicine
Flu protection can get better after 50: a new mRNA shot beat standard-dose vaccines and is now reaching U.S. pharmacies
Reported by everydayhealth.com
Publisher date:
U.S. pharmacies and immunization sites have begun offering mFlusiva, the first mRNA flu vaccine, to adults 50 and older. In a trial involving more than 40,000 adults, it was about 27 percent more effective than a standard-dose vaccine at preventing laboratory-confirmed flu.
Adults over 50 have another available prevention option, with evidence of better protection than standard-dose shots, although confirmation of clinical benefit for those 65 and older remains pending.
Read the original report at everydayhealth.com (opens in a new tab) →
Read the full front page of Friday, 9 October 2026 →
Get tomorrow's front page
Five reasons to believe in progress, delivered once a day.